These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Macular Morphology and Visual Acuity in the Second Year of the Comparison of Age-Related Macular Degeneration Treatments Trials. Sharma S; Toth CA; Daniel E; Grunwald JE; Maguire MG; Ying GS; Huang J; Martin DF; Jaffe GJ; Ophthalmology; 2016 Apr; 123(4):865-75. PubMed ID: 26783095 [TBL] [Abstract][Full Text] [Related]
7. Early Predictive Factors of Visual Loss at 1 Year in Neovascular Age-Related Macular Degeneration under Anti-Vascular Endothelial Growth Factor. Kodjikian L; Rezkallah A; Decullier E; Aulagner G; Huot L; Mathis T; Ophthalmol Retina; 2022 Feb; 6(2):109-115. PubMed ID: 33991711 [TBL] [Abstract][Full Text] [Related]
8. Macular Morphology and Visual Acuity in Year Five of the Comparison of Age-related Macular Degeneration Treatments Trials. Jaffe GJ; Ying GS; Toth CA; Daniel E; Grunwald JE; Martin DF; Maguire MG; Ophthalmology; 2019 Feb; 126(2):252-260. PubMed ID: 30189282 [TBL] [Abstract][Full Text] [Related]
9. Ranibizumab and Bevacizumab for Treatment of Neovascular Age-related Macular Degeneration: Two-Year Results. ; ; Martin DF; Maguire MG; Fine SL; Ying GS; Jaffe GJ; Grunwald JE; Toth C; Redford M; Ferris FL Ophthalmology; 2020 Apr; 127(4S):S135-S145. PubMed ID: 32200813 [TBL] [Abstract][Full Text] [Related]
10. Macular Atrophy in the HARBOR Study for Neovascular Age-Related Macular Degeneration. Sadda SR; Tuomi LL; Ding B; Fung AE; Hopkins JJ Ophthalmology; 2018 Jun; 125(6):878-886. PubMed ID: 29477692 [TBL] [Abstract][Full Text] [Related]
11. Comparing the Efficacy of Bevacizumab and Ranibizumab in Patients with Diabetic Macular Edema (BRDME): The BRDME Study, a Randomized Trial. Vader MJC; Schauwvlieghe AME; Verbraak FD; Dijkman G; Hooymans JMM; Los LI; Zwinderman AH; Peto T; Hoyng CB; van Leeuwen R; Vingerling JR; Moll AC; van Lith-Verhoeven JJC; Dijkgraaf MGW; Schlingemann RO; Ophthalmol Retina; 2020 Aug; 4(8):777-788. PubMed ID: 32362552 [TBL] [Abstract][Full Text] [Related]
12. Canadian Treat-and-Extend Analysis Trial with Ranibizumab in Patients with Neovascular Age-Related Macular Disease: One-Year Results of the Randomized Canadian Treat-and-Extend Analysis Trial with Ranibizumab Study. Kertes PJ; Galic IJ; Greve M; Williams RG; Rampakakis E; Scarino A; Sheidow T Ophthalmology; 2019 Jun; 126(6):841-848. PubMed ID: 30677465 [TBL] [Abstract][Full Text] [Related]
13. A randomised controlled trial to assess the clinical effectiveness and cost-effectiveness of alternative treatments to Inhibit VEGF in Age-related choroidal Neovascularisation (IVAN). Chakravarthy U; Harding SP; Rogers CA; Downes S; Lotery AJ; Dakin HA; Culliford L; Scott LJ; Nash RL; Taylor J; Muldrew A; Sahni J; Wordsworth S; Raftery J; Peto T; Reeves BC Health Technol Assess; 2015 Oct; 19(78):1-298. PubMed ID: 26445075 [TBL] [Abstract][Full Text] [Related]
14. Comparison of ranibizumab and bevacizumab for neovascular age-related macular degeneration according to LUCAS treat-and-extend protocol. Berg K; Pedersen TR; Sandvik L; Bragadóttir R Ophthalmology; 2015 Jan; 122(1):146-52. PubMed ID: 25227499 [TBL] [Abstract][Full Text] [Related]
15. Outcomes by Baseline Choroidal Neovascularization Features in Age-Related Macular Degeneration: A Post Hoc Analysis of the VIEW Studies. Steinle NC; Du W; Gibson A; Saroj N Ophthalmol Retina; 2021 Feb; 5(2):141-150. PubMed ID: 32652314 [TBL] [Abstract][Full Text] [Related]
16. Macular Atrophy in Neovascular Age-Related Macular Degeneration: A Randomized Clinical Trial Comparing Ranibizumab and Aflibercept (RIVAL Study). Gillies MC; Hunyor AP; Arnold JJ; Guymer RH; Wolf S; Pecheur FL; Munk MR; McAllister IL Ophthalmology; 2020 Feb; 127(2):198-210. PubMed ID: 31619357 [TBL] [Abstract][Full Text] [Related]
17. Baseline Predictors of 12-Month Treatment Response to Ranibizumab in Patients With Wet Age-Related Macular Degeneration. Regillo CD; Busbee BG; Ho AC; Ding B; Haskova Z Am J Ophthalmol; 2015 Nov; 160(5):1014-1023.e2. PubMed ID: 26231305 [TBL] [Abstract][Full Text] [Related]
18. Archway Randomized Phase 3 Trial of the Port Delivery System with Ranibizumab for Neovascular Age-Related Macular Degeneration. Holekamp NM; Campochiaro PA; Chang MA; Miller D; Pieramici D; Adamis AP; Brittain C; Evans E; Kaufman D; Maass KF; Patel S; Ranade S; Singh N; Barteselli G; Regillo C; Ophthalmology; 2022 Mar; 129(3):295-307. PubMed ID: 34597713 [TBL] [Abstract][Full Text] [Related]
19. Worth changing? Clinical effects of switching treatment in neovascular age-related macular degeneration from intravitreal ranibizumab and aflibercept to bevacizumab in a region in southern Sweden. Bro T; Hägg S Eur J Ophthalmol; 2021 Jan; 31(1):144-148. PubMed ID: 31642333 [TBL] [Abstract][Full Text] [Related]
20. Baseline predictors for one-year visual outcomes with ranibizumab or bevacizumab for neovascular age-related macular degeneration. Ying GS; Huang J; Maguire MG; Jaffe GJ; Grunwald JE; Toth C; Daniel E; Klein M; Pieramici D; Wells J; Martin DF; Ophthalmology; 2013 Jan; 120(1):122-9. PubMed ID: 23047002 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]